Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

41.15 +1.64 (+4.15%)
Streaming Delayed Price Updated: 12:32 PM EDT, Jun 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Christopher Hite to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.